SCCA Clinical Studies: Phase 1 Program

Phase I studies are critical to future patients and the health-care industry. Potentially speeding the development of new therapies, phase I studies require a high level of unique technical and scientific competencies, like those found at SCCA’s Phase I Cancer Clinical Trials Program.

Located in the Clinical Trials Unit (CTU) at SCCA, our program’s researchers have access to leading research facilities at Fred Hutchinson Cancer Research Center, the source of multiple medical breakthroughs and home to Nobel Prize winning researchers, and University of Washington Medicine where advanced technologies such as positron emission tomography (PET) and other essential tools support thorough research studies.

We're currently enrolling patients into the following trials:

All solid tumor malignancies

• LDK378 for Tumors with ALK Mutation
  A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK).
• PF-05082566 for Advanced Cancer or B-Cell Lymphoma
  A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
• RO5429083 Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
  Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
• IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
  A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors

Breast Cancer

• PARP Inhibitor ABT-888 with Cisplatin and Vinorelbine
  Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.

GI Cancer

• IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
  A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
• RO5429083 Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
  Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
• PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
  A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

 GU Cancer

• RO5429083 Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
  Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

Gynecologic Cancer

• RO5429083 Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
  Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

Head & Neck Cancers

• IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
  A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
  A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

• PF-04449913 w/ Chemotherapy for AML or MDS
  A Phase 1B Study To Evaluate The Safety And Preliminary Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome
• PF-05082566 for Advanced Cancer or B-Cell Lymphoma
  A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
• Oral LDK378 for Patients With ALK-positive Tumors
  A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK).

Lung Cancer

• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
  A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer
• Oral LDK378 for Patients With ALK-positive Tumors
  A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK).
• IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
  A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors

Melanoma

• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
  A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer
• IL-21/Ipilimumab Combination for Melanoma
  A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma.

Renal Cell Carcinoma

• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
  A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer
• AGS-16C3F Monotherapy for Renal Cell Carcinoma
  A Phase I, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects with Renal Cell Carcinoma of Clear Cell or Papillary Histology.
• SGN-75 + Everolimus for Metastatic Renal Cell Carcinoma
  A phase 1b, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma
• IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
  A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors

• Imatinib and BKM120 for 3rd Line GIST Patients
  A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib
• MORAb-004 + Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma
  A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma
• Pazopanib Hydrochloride Followed By Chemotherapy and Surgery for Soft Tissue Sarcoma
  The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging.
• IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
  A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors